These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 28441956)

  • 1. What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism.
    ; Tougher S; Hanson K; Goodman C
    Malar J; 2017 Apr; 16(1):173. PubMed ID: 28441956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the Affordable Medicines Facility--malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data.
    Tougher S; ; Ye Y; Amuasi JH; Kourgueni IA; Thomson R; Goodman C; Mann AG; Ren R; Willey BA; Adegoke CA; Amin A; Ansong D; Bruxvoort K; Diallo DA; Diap G; Festo C; Johanes B; Juma E; Kalolella A; Malam O; Mberu B; Ndiaye S; Nguah SB; Seydou M; Taylor M; Rueda ST; Wamukoya M; Arnold F; Hanson K
    Lancet; 2012 Dec; 380(9857):1916-26. PubMed ID: 23122217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing times: trends in availability, price, and market share of malaria diagnostics in the public and private healthcare sector across eight sub-Saharan African countries from 2009 to 2015.
    ; Hanson K; Goodman C
    Malar J; 2017 May; 16(1):205. PubMed ID: 28526075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries.
    O'Connell KA; Gatakaa H; Poyer S; Njogu J; Evance I; Munroe E; Solomon T; Goodman C; Hanson K; Zinsou C; Akulayi L; Raharinjatovo J; Arogundade E; Buyungo P; Mpasela F; Adjibabi CB; Agbango JA; Ramarosandratana BF; Coker B; Rubahika D; Hamainza B; Chapman S; Shewchuk T; Chavasse D
    Malar J; 2011 Oct; 10():326. PubMed ID: 22039838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Artemisinin-based combination therapy availability and use in the private sector of five AMFm phase 1 countries.
    Davis B; Ladner J; Sams K; Tekinturhan E; de Korte D; Saba J
    Malar J; 2013 Apr; 12():135. PubMed ID: 23607504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subsidising artemisinin-based combination therapy in the private retail sector.
    Opiyo N; Yamey G; Garner P
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009926. PubMed ID: 26954551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do anti-malarials in Africa meet quality standards? The market penetration of non quality-assured artemisinin combination therapy in eight African countries.
    ; Newton PN; Hanson K; Goodman C
    Malar J; 2017 May; 16(1):204. PubMed ID: 28539125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Affordable Medicines Facility-malaria (AMFm): are remote areas benefiting from the intervention?
    Ye Y; Arnold F; Noor A; Wamukoya M; Amuasi J; Blay S; Mberu B; Ren R; Kyobutungi C; Wekesah F; Gatakaa H; Toda M; Njogu J; Evance I; O'Connell K; Shewchuk T; Thougher S; Mann A; Willey B; Goodman C; Hanson K
    Malar J; 2015 Oct; 14():398. PubMed ID: 26452625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The malaria testing and treatment landscape in Kenya: results from a nationally representative survey among the public and private sector in 2016.
    ; Musuva A; Ejersa W; Kiptui R; Memusi D; Abwao E
    Malar J; 2017 Dec; 16(1):494. PubMed ID: 29268789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-seeking patterns for malaria in pharmacies in five sub-Saharan African countries.
    Ladner J; Davis B; Audureau E; Saba J
    Malar J; 2017 Aug; 16(1):353. PubMed ID: 28851358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience of healthcare personnel on Co-payment mechanism and the implications on its use in private drug outlets in Uganda.
    Ocan M; Bakubi R; Nakalembe L; Ekusai-Sebatta D; Sam N
    PLoS One; 2024; 19(5):e0297416. PubMed ID: 38758832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The malaria testing and treatment landscape in mainland Tanzania, 2016.
    ; Michael D; Mkunde SP
    Malar J; 2017 Apr; 16(1):202. PubMed ID: 28521811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Has Tanzania embraced the green leaf? Results from outlet and household surveys before and after implementation of the Affordable Medicines Facility-malaria.
    Thomson R; Festo C; Johanes B; Kalolella A; Bruxvoort K; Nchimbi H; Tougher S; Cairns M; Taylor M; Kleinschmidt I; Ye Y; Mann A; Ren R; Willey B; Arnold F; Hanson K; Kachur SP; Goodman C
    PLoS One; 2014; 9(5):e95607. PubMed ID: 24816649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing availability, prices, and market share of quality-assured malaria ACT and RDT in the private retail sector in Nigeria and Uganda.
    Woldeghebriel M; Aso E; Berlin E; Fashanu C; Kirumira SN; Lam F; Mugerwa R; Nakiganda J; Olaleye T; Opigo J; Osinupebi F; Priestley N; Stringham R; Uhomoibhi P; Visser T; Ward A; Wiwa O; Woolsey A
    Malar J; 2024 Feb; 23(1):41. PubMed ID: 38321459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme.
    Smith N; Obala A; Simiyu C; Menya D; Khwa-Otsyula B; O'Meara WP
    Malar J; 2011 Oct; 10():316. PubMed ID: 22029829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Private sector role, readiness and performance for malaria case management in Uganda, 2015.
    ; Kaula H; Buyungo P; Opigo J
    Malar J; 2017 May; 16(1):219. PubMed ID: 28545583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cross-sectional study of the availability and price of anti-malarial medicines and malaria rapid diagnostic tests in private sector retail drug outlets in rural Western Kenya, 2013.
    Kioko U; Riley C; Dellicour S; Were V; Ouma P; Gutman J; Kariuki S; Omar A; Desai M; Buff AM
    Malar J; 2016 Jul; 15(1):359. PubMed ID: 27406179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of the private sector co-payment mechanism (PSCM) on the private market for ACT in Nigeria: results of the 2018 cross-sectional outlet and household market surveys.
    Edwards HM; Sarwar R; Mahmud P; Emmanuel S; Maxwell K; Tibenderana JK
    Malar J; 2022 Feb; 21(1):42. PubMed ID: 35151332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in availability and prices of subsidized ACT over the first year of the AMFm: evidence from remote regions of Tanzania.
    Yadav P; Cohen JL; Alphs S; Arkedis J; Larson PS; Massaga J; Sabot O
    Malar J; 2012 Aug; 11():299. PubMed ID: 22929587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets.
    Ocan M; Nambatya W; Otike C; Nakalembe L; Nsobya S
    PLoS One; 2024; 19(3):e0295198. PubMed ID: 38536824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.